Turkish Version of Ottawa Sitting Scale in Patients With Stroke

Sponsor
Gulhane School of Medicine (Other)
Overall Status
Recruiting
CT.gov ID
NCT04752878
Collaborator
(none)
80
1
15
5.3

Study Details

Study Description

Brief Summary

The aim of the study is to describe the cultural adaptation of the Ottawa Sitting Scale and to examine the factor structure, reliability and validity of the scale in patients with stroke.

The scale will be translated into Turkish language by following the procedure. 80 patients will be recruited in the study. Berg Balance Scale and Trunk Impairment Scale will be included with Turkish Ottawa Sitting Scale to test the validity. Outcome measures will be repeated by a second physiotherapist the day after the first assessment for interrater reliability and conducted twice within 2 weeks (test-retest) for reliability.

The interrater and intrarater reliability of the Ottawa sitting scale will be determined using intraclass correlation coefficients and internal consistency will be assessed using Cronbach's alpha.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Ottawa sitting scale

Study Design

Study Type:
Observational
Anticipated Enrollment :
80 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
The Turkish Version Of The Ottawa Sitting Scale: Its Cultural Adaptation, Validation And Reliability In Patients Wıth Stroke
Actual Study Start Date :
May 15, 2021
Actual Primary Completion Date :
Jun 15, 2022
Anticipated Study Completion Date :
Aug 15, 2022

Outcome Measures

Primary Outcome Measures

  1. Ottawa sitting scale [Measurements will start with the first patient hospitalized (estimated in March 2021) and end with the evaluation of the 80th patient (estimated period of 12 months)]

    A balance measurement scale for acute stroke patients. The scale tests the patient on a total of 10 items while sitting, with 5 items with eyes open and 5 items with eyes closed. An ordered scale (0-4) is used to score each item. The total score range of the scale is 0-40. Higher scores indicate a better outcome

Secondary Outcome Measures

  1. Berg balance scale [Measurements will start with the first patient hospitalized (estimated in March 2021) and end with the evaluation of the 80th patient (estimated period of 12 months)]

    A balance measurement to determine the risk of falls. The scale consists of 14 items. Each item is scored between 0 and 4. 4 points indicate the ability to complete the task independently, 0 points indicate the failure to start the task. According to the scores, the cases are divided into groups as "high risk of falling (0-20 points)", "moderate fall risk (21-40 points)", "low risk of falling (41-56 points)" and the highest score 56 is considered to show the best balance

  2. Trunk Impairment scale [Measurements will start with the first patient hospitalized (estimated in March 2021) and end with the evaluation of the 80th patient (estimated period of 12 months)]

    A scale to evaluate motor disorders in the trunk after stroke. This scale consists of 3 sub-sections and 17 items that evaluate static sitting balance, dynamic sitting balance and coordination. The maximum score of the test is 40 points. High scores indicate good balance

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Diagnosed with acute stroke

  • aged above 18 years

Exclusion Criteria:
  • Patients who do not cooperate enough to read or approve the consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sağlık Bilimleri Üniversitesi Ankara Turkey 06310

Sponsors and Collaborators

  • Gulhane School of Medicine

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Mustafa Ertuğrul Yaşa, Assistant professor, Gulhane School of Medicine
ClinicalTrials.gov Identifier:
NCT04752878
Other Study ID Numbers:
  • 2020-363
First Posted:
Feb 12, 2021
Last Update Posted:
Jul 11, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 11, 2022